Ulaanbaatar
Quality control tests being carried out for immunoglobulin at Biopreparation Production Plant
Society
Ulaanbaatar /MONTSAME/. The Biopreparation Production Plant of the National Center for Public Health has begun to manufacture immunoglobulin and carry out tests for quality control. Immunoglobulin is commonly used for the prevention and treatment of viral and bacterial illnesses.
More specifically, it was decided to restore the operations of the Biopreparation Production Plant, which was stopped in 2010. Thus, Director General of the National Center for Public Health D.Narantuya and Head of the Biotechnology and Innovation Department B.Ichinkhorloo informed Deputy Prime Minister S.Amarsaikhan about the manufacturing of immunoglobulin as well as its quality control on August 6.
The plant has a capacity of manufacturing 1,500-3,000 doses from 60-100 liters of plasma in 45 days.
Previously, Mongolia has used immunoglobulin in the prevention and treatment of diseases such as jaundice, measles, and meningitis. Thus, researchers highlight that it is possible for the product to be more effective in treating COVID-19 patients as well as for the treatment of other viral diseases and taking preventive measures against secondary bacterial infections as it is based on studies that have been carried out in the past. With its production, it will also become possible to reduce the costs for purchasing imported products, reducing currency outflow.
